Iopromide
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Iopromide: From Diagnostic Contrast Imaging to Osteoarthritis
One-Sentence Summary
Iopromide is an iodinated, non-ionic radiographic contrast agent, marketed in Canada as ULTRAVIST. The TxGNN model predicts it may be effective for osteoarthritis, but no clinical trials and no publications were found to support this prediction. It is a TxGNN model (deep learning) result only, which may reflect similarities the model learned between related diseases, and it is not backed by any pharmacological rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the Canadian licence records contain no indication text); known use is as a radiographic contrast agent |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 0.9953 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Iopromide is an iodinated, non-ionic contrast medium. It is used to make structures visible on imaging, not to treat disease.
No credible mechanistic link to osteoarthritis was identified. The drug has no known anti-inflammatory or cartilage-protective activity. Use of contrast agents in joint imaging (arthrography) is a diagnostic procedure, not a therapeutic effect.
The high score of 0.9953 comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The other top predictions (rheumatoid arthritis, brachyolmia, acromesomelic dysplasia Hunter-Thompson type, brachyolmia-amelogenesis imperfecta syndrome, alopecia, myosclerosis, hemoglobinopathy and pseudoachondroplasia) show the same pattern. None has clinical trials, literature or a plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02078619 | ULTRAVIST 370 | Not specified | Not specified |
| 02078600 | ULTRAVIST 300 | Not specified | Not specified |
Both are single-ingredient products with valid status.
Safety Considerations
- Drug Interactions: The interaction query completed with 100 recorded interactions. Most of those listed are rated Major. Examples:
- Metformin
- Amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms)
- Vancomycin
- Aminoglycosides (kanamycin, neomycin, streptomycin)
- Polymyxin B
- Mesalazine, balsalazide, olsalazine and sulfasalazine
Mannitol is rated Moderate. Clotrimazole, acetylsalicylic acid, bupropion, dexamethasone and pantoprazole are of unknown severity.
Warnings and contraindications from the Canadian package insert were not available for this report. Please refer to the package insert for them.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN model (deep learning) score. No clinical trial or publication studies iopromide in osteoarthritis, and no plausible therapeutic mechanism exists for a diagnostic contrast agent. The evidence level is therefore L5.
To proceed, the following is needed:
- Health Canada package insert warnings, contraindications and approved indication text
- Mechanism of action data
- Preclinical or mechanistic evidence showing a therapeutic effect in osteoarthritis
- Route and formulation compatibility assessment for any therapeutic use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.